---
schema_version: "secwatch.filing_event.v1"
accession: "0001159036-25-000047"
form_type: "8-K"
ticker: "HALO"
cik: "0001159036"
company_name: "HALOZYME THERAPEUTICS, INC."
filed_at: "2025-11-05T23:59:59+00:00"
generated_at: "2026-05-17T00:11:13.760583+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Halozyme to offer $1.3B in convertible notes; extends credit facility to $750M

## Summary
- Amended credit facility: commitments increased to $750M, maturity extended to Nov 5, 2030; no outstanding borrowings.
- Proposes $650M 2031 notes and $650M 2032 notes; option for additional $100M each.
- Net proceeds partly fund capped call transactions to reduce potential dilution upon conversion.
- Plans to repurchase existing 0.25% 2027 and 1.00% 2028 convertible notes via private deals.
- Remaining proceeds for general corporate purposes, including working capital and acquisitions.

## SEC filing metadata
- accession: 0001159036-25-000047
- form_type: 8-K
- ticker: HALO
- cik: 0001159036
- company_name: HALOZYME THERAPEUTICS, INC.
- filed_at: 2025-11-05T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 2.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1159036/000115903625000047/0001159036-25-000047-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1159036/000115903625000047/halo-20251105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001159036-25-000047
- JSON: https://secwatch.observer/filing/0001159036-25-000047.json
- Plain text: https://secwatch.observer/filing/0001159036-25-000047.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.